This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zeng, G. Articles by Yu, R. K. Search for Related Content PubMed PubMed Citation Articles by Zeng, G. Articles by Yu, R. K.

Suppression of Ganglioside GD3 Expression in a Rat F-11 Tumor Cell Line Reduces Tumor Growth, Angiogenesis, and Vascular Endothelial Growth Factor Production¹

Institute of Molecular Medicine and Genetics, Medical College of Georgia, Augusta, Georgia 30912

Ganglioside GD3 is overexpressed in many types of tumors and may be associated with tumor progression and the development of metastatic potential. In our previous study (G. Zeng et al., Biochemistry, 38: 8762–8769, 1999), we established a subclone of the rat dorsal root ganglion-derived F-11 cells in which the expression of ganglioside GD3 was inhibited by stable transfection of the antisense vector against CMP-NeuAc:GM3 2–8 sialyltransferase (GD3-synthase) gene. This cell line exhibits markedly reduced rate of tumor growth in vivo. Here, we further characterized the antisense-transfected cell line, and the results showed that these cells formed small, minimally vascularized tumors exhibiting extensive necrosis. In vivo Matrigel assay revealed reduced vascularization and low hemoglobin content in the antisense xenografts. Significantly fewer new vessels were found on the antisense xenografts and the skin around them than those on/around the xenografts formed by the sense-transfected and untransfected F-11 cells. The hemoglobin content of the antisense xenografts was much lower than that of the xenografts formed by the control cells. The reduced angiogenesis in the antisense xenografts was correlated with a decrease in vascular endothelial growth factor (VEGF) production. The expression of VEGF was suppressed in the antisense xenografts and the conditioned culture media of the antisense-transfected F-11 cells as determined by Western blotting analysis. This was further confirmed by immunohistochemistry of the tumors using antibodies against VEGF and platelet/endothelial cell adhesion molecule (PECAM-1). Therefore, our results demonstrate that reduced tumor growth in nude mice by suppression of GD3-synthase expression in F-11 cells results from minimal angiogenesis of the tumors through down-regulation of the VEGF expression, which indicates an important role for GD3 in tumor angiogenesis.

This article has been cited by other articles:

				T.-W. Chung, S.-J. Kim, H.-J. Choi, K.-J. Kim, M.-J. Kim, S.-H. Kim, H.-J. Lee, J.-H. Ko, Y.-C. Lee, A. Suzuki, et al. Ganglioside GM3 inhibits VEGF/VEGFR-2-mediated angiogenesis: Direct interaction of GM3 with VEGFR-2 Glycobiology, March 1, 2009; 19(3): 229 - 239. [Abstract] [Full Text] [PDF]

				Y.-H. Liu, C.-Y. Lin, W.-C. Lin, S.-W. Tang, M.-K. Lai, and J.-Y. Lin Up-Regulation of Vascular Endothelial Growth Factor-D Expression in Clear Cell Renal Cell Carcinoma by CD74: A Critical Role in Cancer Cell Tumorigenesis J. Immunol., November 1, 2008; 181(9): 6584 - 6594. [Abstract] [Full Text] [PDF]

				P. Mukherjee, A. C. Faber, L. M. Shelton, R. C. Baek, T. C. Chiles, and T. N. Seyfried Thematic Review Series: Sphingolipids. Ganglioside GM3 suppresses the proangiogenic effects of vascular endothelial growth factor and ganglioside GD1a J. Lipid Res., May 1, 2008; 49(5): 929 - 938. [Abstract] [Full Text] [PDF]

				M. Noguchi, K. Kabayama, S. Uemura, B.-w. Kang, M. Saito, Y. Igarashi, and J.-i. Inokuchi Endogenously produced ganglioside GM3 endows etoposide and doxorubicin resistance by up-regulating Bcl-2 expression in 3LL Lewis lung carcinoma cells Glycobiology, July 1, 2006; 16(7): 641 - 650. [Abstract] [Full Text] [PDF]

				K. Hamamura, K. Furukawa, T. Hayashi, T. Hattori, J. Nakano, H. Nakashima, T. Okuda, H. Mizutani, H. Hattori, M. Ueda, et al. Ganglioside GD3 promotes cell growth and invasion through p130Cas and paxillin in malignant melanoma cells PNAS, August 2, 2005; 102(31): 11041 - 11046. [Abstract] [Full Text] [PDF]

				E. Masson, N. Wiernsperger, M. Lagarde, and S. El Bawab Involvement of gangliosides in glucosamine-induced proliferation decrease of retinal pericytes Glycobiology, June 1, 2005; 15(6): 585 - 591. [Abstract] [Full Text] [PDF]

				Y. Liu, R. Li, and S. Ladisch Exogenous Ganglioside GD1a Enhances Epidermal Growth Factor Receptor Binding and Dimerization J. Biol. Chem., August 27, 2004; 279(35): 36481 - 36489. [Abstract] [Full Text] [PDF]

				W. Zou, S. Borrelli, M. Gilbert, T. Liu, R. A. Pon, and H. J. Jennings Bioengineering of Surface GD3 Ganglioside for Immunotargeting Human Melanoma Cells J. Biol. Chem., June 11, 2004; 279(24): 25390 - 25399. [Abstract] [Full Text] [PDF]

				M. Weiss, S. Hettmer, P. Smith, and S. Ladisch Inhibition of Melanoma Tumor Growth by a Novel Inhibitor of Glucosylceramide Synthase Cancer Res., July 1, 2003; 63(13): 3654 - 3658. [Abstract] [Full Text] [PDF]

				S. Hakomori Glycosylation defining cancer malignancy: New wine in an old bottle PNAS, August 6, 2002; 99(16): 10231 - 10233. [Full Text] [PDF]